Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer disease

References

• Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158:47 - 52
   PubMed Web of Science ®Google Scholar
• Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 2000; 74:270 - 279
   PubMed Web of Science ®Google Scholar
• Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, et al. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 2003; 278:17401 - 17407
   PubMed Web of Science ®Google Scholar
• Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 2002; 23:1031 - 1038
   PubMed Web of Science ®Google Scholar
• Walshe JM. Clinical Investigations standing Committee of the association of Clinical Biochemists. Wilson's disease: the importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003; 40:115 - 121
   PubMed Web of Science ®Google Scholar
• Hoogenraad TU. Monography: Wilson's disease. Major Problems in Neurology 1996; 30 London W.B. Saunders
   Google Scholar
• Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, et al. Elevated cortical zinc in Alzheimer disease. Neurology 2006; 67:69 - 75
   PubMed Web of Science ®Google Scholar
• Molina JA, Jiménez-Jiménez FJ, Aguilar MV, Meseguer I, Mateos-Vega CJ, González-Muñoz MJ, et al. Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 1998; 105:479 - 488
   PubMed Web of Science ®Google Scholar
• Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper and zinc blood concentrations in patients with Alzheimer Disease: cross-sectional study. Croat Med J 2002; 43:28 - 32
   PubMed Web of Science ®Google Scholar
• Sedighi B, Shafa MA, Shariati M. A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia 2006; 11:107 - 109
   Google Scholar
• Snaedal J, Kristinsson J, Gunnarsdóttir S, Olafsdóttir Baldvinsson M, Jóhannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease: a case-control study. Dement Geriatr Cogn Disord 1998; 9:239 - 242
   PubMed Web of Science ®Google Scholar
• González C, Martín T, Cacho J, Breñas MT, Arroyo T, García-Berrocal B, et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 1999; 29:637 - 642
   PubMed Web of Science ®Google Scholar
• Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurol 2002; 59:1153 - 1161
   PubMed Web of Science ®Google Scholar
• Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, et al. Trace elements and cognitive impairment: an elderly cohort study. Arch Gerontol Geriatr Suppl 2004; 204:393 - 402
   Google Scholar
• Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid and h-tau. Neurology 2006; 67:76 - 82
   PubMed Web of Science ®Google Scholar
• Pajonk FG, Kessler H, Supprian T, Hamzei P, Bach D, Schweickhardt J, et al. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimer's Dis 2005; 8:23 - 27
   PubMed Web of Science ®Google Scholar
• Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, et al. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. Neural Transm 2006; 113:1763 - 1769
   PubMed Web of Science ®Google Scholar
• Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurol 2005; 64:1040 - 1046
   PubMed Web of Science ®Google Scholar
• Hoogenraad TU. Frijns CJM, Kappelle LJ, Klijn CJM. Measuring hypercupremia in blood of patients with Alzheimer's disease is logical, but the utility of measuring free-copper has to be proven. Wokke JHJ Neurologie 2007; Utrechts Tijdschrift voor 111 - 112
   Google Scholar
• Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 2008; 21:367 - 372
   PubMed Web of Science ®Google Scholar
• Terada K, Schilsky ML, Miura N, Sugiyama T. ATP7B (WND) protein. Int J Biochem Cell Biol 1998; 30:1063 - 1067
   PubMed Web of Science ®Google Scholar
• Shim H, Harris ZL. Genetic defects in copper metabolism. J Nutr 2003; 133:1527 - 1531
   Google Scholar
• Bielli P, Calabrese L. Structure to function relationships in ceruloplasmin: a ‘moonlighting’ protein. Cell Mol Life Sci 2002; 59:1413 - 1427
   PubMed Web of Science ®Google Scholar
• Squitti R, Ventriglia M, Barbati G, Cassetta E, Ferreri F, Dal Forno G, et al. ‘Free’ copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 2007; 114:1589 - 1594
   PubMed Web of Science ®Google Scholar
• White AR, Reyes R, Mercer JF, Camakaris J, Zheng H, Bush AI, et al. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res 1999; 842:439 - 444
   PubMed Web of Science ®Google Scholar
• Strozyk D, Launer LJ, Adlard PA, Cherny RA, Tsatsanis A, Volitakis I, et al. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging 2007; [Epub ahaed of print]
   Web of Science ®Google Scholar
• Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002; 277:40302 - 40308
   PubMed Web of Science ®Google Scholar
• Musci G, Bonaccorsi di Patti MC, Fagiolo U, Calabrese L. Age-related changes in human ceruloplasmin. Evidence for oxidative modifications. J Biol Chem 1993; 268:13388 - 13395
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol 1984; 34:939 - 944
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh RR. ”Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189 - 198
   PubMed Web of Science ®Google Scholar
• Abe A, Yamashita S, Noma A. Sensitive direct colorimetric assay for copper in serum. Clin Chem 1989; 35:552 - 554
   PubMed Web of Science ®Google Scholar